Pfizer Australia and MSD
will co-promote MSD’s DPP4
inhibitor (sitagliptin) franchise,
with representatives from both
companies promoting Januvia
(sitagliptin), Janumet (sitagliptin/
metformin) and soon to be PBS
listed Janumet XR (sitagliptin/
metformin extended release).
This follows the global
arrangement between the
companies, announced in April last
year, to develop and commercialise
Pfizer’s oral sodium glucose
cotransporter inhibitor, which has
started phase III trials.
Pfizer head of marketing James
Price said it allowed the companies
to start their collaboration in
the diabetes space earlier, giving
experience in working together.The above article was sent to subscribers in Pharmacy Daily's issue from 31 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Mar 14
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.